Takeda Pharmaceuticals America Inc (TAK) all U.S. Lobbying: all historical lobbying contracts, government bills & agencies, and critical issues lobbied on.

$99.95

Discover Takeda Pharmaceuticals America Inc’s lobbying activities with our comprehensive dataset, offering insights on spending, bills, and issues from 1999-present. Analyze data by company, lobbyist, issue, and more through our intelligently crafted data design. Dataset updated weekly.

Description

Using our intelligently designed and intuitive dataset, you can quickly understand how Takeda Pharmaceuticals America Inc (TAK) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.

Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.

For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.

Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.

Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:

1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.

2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.

3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).

4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.

5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).

6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).

7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).

Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].

Frequently Asked Questions

What is Takeda Pharmaceuticals America Inc (TAK) lobbying for?

Summary of Lobbying Data:

Takeda Pharmaceuticals America Inc hired multiple lobbying firms to lobby on various general and specific issues, including taxation, health issues, Medicare/Medicaid, copyright/patent/trademark, trade (domestic/foreign), and budget/appropriations. They lobbied on specific issues such as mental health, prescription drug prices, drug research and innovation, patient access to plasma therapies, and value-based drug contracting. They lobbied government agencies such as the White House Office, House of Representatives, Senate, Centers for Medicare and Medicaid Services (CMS), and Executive Office of the President (EOP).

One could infer that Takeda Pharmaceuticals America Inc is lobbying on these issues to influence policies and regulations that may affect their business operations and profits. They may also be advocating for policies that promote access to their pharmaceutical products and development of new drugs, as well as advocating for tax incentives and favorable budgetary appropriations for research and development.

Subscribe To Our Newsletter

gain actionable insights from our alternative data

More to explore